<DOC>
	<DOCNO>NCT00364871</DOCNO>
	<brief_summary>The purpose study determine efficacy safety 3 combination naltrexone bupropion SR compare naltrexone alone , bupropion SR alone placebo .</brief_summary>
	<brief_title>Efficacy Safety Study Combination Therapy Treat Uncomplicated Obesity</brief_title>
	<detailed_description>A complete proof concept study , OT-101 ( Data File , Orexigen Therapeutics , 2005 ) , demonstrate combination 300 mg bupropion SR 50 mg naltrexone associate great weight loss bupropion SR alone , naltrexone alone , placebo subject uncomplicated obesity . The hypothesis current trial adjusting dose titration schedule bupropion SR naltrexone great efficacy improve tolerability achieve . In trial , high dose bupropion 2 low dos naltrexone utilized previous trial ( OT-101 ) evaluate . The dos drug titrate 4 week administer twice day . There 2 cohort . At site , cohort 2 recruitment begin soon cohort 1 enrollment complete . Cohort 1 treatment group ( 60 per group ) : - Group 1 : Bupropion SR ( 400 mg/day ) plus Naltrexone ( 48 mg/day ) - Group 2 : Bupropion SR ( 400 mg/day ) plus Naltrexone ( 16 mg/day ) - Group 3 : Bupropion SR ( 400 mg/day ) plus N-Placebo - Group 4 : B-placebo plus Naltrexone ( 48 mg/day ) - Group 5 : B-Placebo plus N-Placebo Cohort treatment 2 Groups : - Group 6 : B-Placebo plus N-Placebo ( n=20 ) - Group 7 : Bupropion SR ( 400 mg/day ) plus Naltrexone ( 32 mg/day ) ( n=60 )</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Bupropion hydrochloride , naltrexone hydrochoride drug combination</mesh_term>
	<criteria>Female male subject , 18 60 year age Have body mass index ( BMI ) 30 40 kg/m2 Free clinically significant illness disease determine medical history physical examination Nonsmoker use tobacco nicotine product least 6 month prior baseline Normotensive ( systolic &lt; 140 mm Hg ; diastolic &lt; 90 mm Hg ) . Antihypertensive medication allow exception adrenergic blocker , betablockers clonidine . Medical regimen must stable least 6 week LDL cholesterol &lt; 190 mg/dL triglyceride &lt; 400 mg/dL . Medications treatment dyslipidemia allow long medical regimen stable least 6 week No clinically significant abnormality serum albumin , blood urea nitrogen , creatinine , calcium phosphorus Bilirubin , ALT AST within 1.5 x ULN No clinically significant abnormality hematocrit , white blood cell count , white cell differential , platelet Fasting glucose less 140 mg/dL hypoglycemic agent No clinically significant abnormality urinalysis TSH within 1.5 x ULN , normal T3 , TSH low limit normal Negative serum pregnancy test woman intact uterus Score &lt; 11 depression score &lt; 11 anxiety Hospital Anxiety Depression ( HAD ) Scale ECG : clinically significant abnormality Score zero Mood Assessment questionnaire response `` No '' Bipolar Disorder Questions If female childbearing potential , must nonlactating agree use effective contraception throughout study period 30 day discontinuation study drug Able comply require study procedure schedule Willing able give write informed consent Obesity know endocrine origin ( e.g. , untreated hypothyroidism , Cushing 's syndrome ) Serious medical condition medical condition limit participation prescribe exercise program : ( e.g . unstable cardiovascular disease include congestive heart failure , angina pectoris , myocardial infarction ; stroke ; claudication ; acute limb ischemia ; acute renal hepatic disorder ; renal , hepatic respiratory insufficiency ) Active malignancy history malignancy ( nonmelanoma skin cancer surgically cure cervical cancer ) within 5 year enrollment Serious psychiatric condition ( e.g. , history bipolar disorder , psychosis , suicidal attempt postpartum depression ; history major depression , suicidal ideation antidepressant use within 1 year ) Type I Type II diabetes mellitus require pharmacotherapy Excluded concomitant medication : anorectic agent ; weight loss agent ; dietary supplement promote muscle building , enhance mood , reduce appetite ; adrenergic blocker ; beta blocker ; antipsychotic agent ; clonidine ; theophylline ; cimetidine ; oral corticosteroid ; antidepressant ; topiramate ; DepoProveraÂ® , smoke cessation agent ; frequent , know use opioid opioidlike analgesic History surgical intervention obesity History seizure disorder predisposition seizure ( e.g. , history cerebrovascular accident , significant head trauma , brain surgery , skull fracture , subdural hematoma , febrile seizure ) History bulimia anorexia nervosa History drug alcohol abuse within 5 year History treatment bupropion , naltrexone within 12 month History hypersensitivity bupropion , naltrexone Use drug , herb , dietary supplement know significantly affect body weight within one month baseline Use investigational drug , device procedure within 90 day Participation previous clinical trial conduct Orexigen Therapeutics Any condition opinion investigator make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Obesity</keyword>
</DOC>